Top Markets
Coin of the day
Myriad Genetics, Inc. Myriad Genetics, Inc.

Myriad Genetics, Inc.

MYGN
Rankning i aktier #16435
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company,... Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Aktiekurs
$3.12
Senast synkroniserad: 2026-09-01
Marknadsvärde
$294.21M
Förändring (1 dag)
-3.26%
Förändring (1 år)
-54.86%
Land
US
Handel Myriad Genetics, Inc. (MYGN)

Kategori

Pris MYGN med marknadsvärde på B
Myriad Genetics, Inc. Myriad Genetics, Inc.
MYGN
$3.12
Marknadsvärde för Myriad Genetics, Inc.(MYGN)
Marknadsvärde: $294.21M
Från och med September 2026 har Myriad Genetics, Inc. ett börsvärde på $294.21M. Detta gör Myriad Genetics, Inc. till det 16435th mest värdefulla företaget i världen enligt våra data. Börsvärdet, även kallat market cap, är det totala marknadsvärdet av ett börsnoterat företags utestående aktier och används ofta för att uppskatta ett företags värde.
Marknadsvärdehistorik för Myriad Genetics, Inc. från 1995 till 2026
MYGN jämfört med topp 5 mest populära stocks
Pris för MYGN Tillgång B Marknadsvärdet för B Resultat
Myriad Genetics, Inc. Myriad Genetics, Inc.
$55,687.76 $294.21M
$5.260T +1,787,629.19%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$50,594.20 $294.21M
$4.779T +1,624,111.81%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$42,528.50 $294.21M
$4.017T +1,365,181.01%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$39,379.35 $294.21M
$3.719T +1,264,084.73%
Myriad Genetics, Inc. Myriad Genetics, Inc.
$28,949.62 $294.21M
$2.734T +929,261.77%